Cost-Effectiveness of DPYD Genotyping Prior to Capecitabine Administration for Metastatic Breast Cancer

Abstract excerpt

<title>Abstract</title> <p>Purpose Patients with a DPYD genetic deficiency who receive capecitabine are at increased risk of severe, potentially fatal toxicities due to impaired drug metabolism. Genetic testing for this deficiency allows for proactive dose adjustments to mitigate these risks. We evaluated the cost-effectiveness of DPYD genotyping prior to capecitabine administration, followed by dose modification...

Topics

Open a Topic to create a Post that cites this publication.

• Antimetabolites, Antineoplastic
• Breast Neoplasms
• Capecitabine
• Cost-Benefit Analysis
• Dihydrouracil Dehydrogenase (NADP)
• Genotyping Techniques
• Neoplasm Metastasis
• Quality-Adjusted Life Years

Identifiers and source

Literature Corpus work

f5a893a8-ad4b-592d-961d-ab3b99ebd355

DOI

10.21203/rs.3.rs-7992444/v1